The context of tetanus toxoid application influences the outcome of antigen-specific and self-directed humoral immune response

Microbiology and Immunology

Volumn 53, Issue 2, 2009, Pages 89-100

  Stojanović, Marijana ^a   Živković, Irena ^a   Inić Kanada, Aleksandra ^a   Petrušić, Vladimir ^a   Mićić, Mileva ^a   Dimitrijević, Ljiljana ^a  

^a Institute of Virology   (Serbia)

Author keywords

Adjuvant; Anti 2 glycoprotein I antibody; Tetanus toxoid

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; BACTERIAL ANTIGEN; BETA 2 GLYCOPROTEIN 1 ANTIBODY; BETA2 GLYCOPROTEIN 1; FREUND ADJUVANT; GLYCEROL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TETANUS TOXOID; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PREGNANCY; TETANUS PROPHYLAXIS; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; HUMAN; IMMUNIZATION; IMMUNOLOGY;

MUS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; GLYCEROL; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PREGNANCY; TETANUS TOXOID;

EID: 64049108541     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00094.x     Document Type: Article

References (44)

1. Ahmadi K., Wilson C., Tiwana H., Binder A., Ebringer A. (1998) Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis. Rheumatology 37: 1330-3.
2. Bogdanos D.P., Mieli-Vergani G., Vergani D. (2005) Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter? Clin Infect Dis 40(4): 508-10.
3. Chen L.K., Chou Y.C., Tsai S.T., Hwang S.J., Lee S.D. (2005) Hepatitis C virus infection related Type 1 diabetes mellitus. Diabet Med 22(3): 340-3.
4. Tiwana H., Wilson C., Alvarez A., Abuknesha R., Bansal S., Ebringer A. (1999) Crossreactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun 67: 2769-75.
5. Khamaisi M., Shoenfeld Y., Orbach H. (2004) Guillain-Barre syndrome following hepatitis B vaccination. Clin Exp Rheumatol 22(6): 767-70.
6. Mari A. (2004) Is there a causative role of tetanus toxoid vaccination in the development of allergy-like symptoms and the increasing prevalence of atopic diseases? Med Hypotheses 63: 875-86.
7. st century: the genetic response and the innocent bystander. Autoimmun Rev 4: 79-81.
8. Shoenfeld Y., Aron-Moar A. (2000) Vaccination and autoimmunity - "vaccinosis": a dangerous liaison? J Autoimmunity 14: 1-10.
9. Croxford JL, Anger HA, Miller SD. (2005) Viral delivery of an epitope from Haemophilus influenzae induces central nervous system autoimmune disease by molecular mimicry. J Immunol 174(2): 907-17.
10. Samarkos M., Vaiopoulos G. (2005) The role of infections in the pathogenesis of autoimmune diseases. Curr Drug Targets Inflamm Allergy 4(1): 99-103.
11. Wickham S., Carr D.J. (2004) Molecular mimicry versus bystander activation: herpetic stromal keratitis. Autoimmunity 37(5): 393-7.
12. Ramos O.P., Silva E.E., Falcao D.P., Medeiros B.M. (2005) Production of autoantibodies associated with polyclonal activation in Yersinia enterocolitica O: 8-infected mice. Microbiol Immunol 49(2): 129-37.
13. Stojanovic M, Inic-Kanada A, Popovic Z, Zivkovic I, Dimitrijevic L.(2004) Changes in the pools of autoantibodies and anti-bacterial antibodies in patients suffering from recurrent infections of the urinary tract and undergoing bacterial immunization treatment. Immunol Lett 94: 123-33.
14. Farrar J.J., Yen L.M., Cook T., Fairweather N., Binh N., Parry J., Parry C.M. (2000) Neurological aspects of tropical disease: Tetanus. J Neurol Neurosurg Psychiatry 69:292-301.
15. Blank M., Eisenstein M., Ascherson R.A., Cervera R., Schoenfeld Y. (2004) The infectious origin of the antiphospholipid syndrome. In:Schoenfeld Y., Rose N., eds. Infection and Autoimmunity. Amsterdam: Elsevier, pp. 473-90.
16. European Bioinformatics institute - European Molecular Biology Laboratory [Internet], Cambridgeshire, UK, [cited 2008 June 2]. Available from http://www.ebi.ac.uk/t-coffee/
17. Galili U. (1996) Alpha-galactosyl (anti-Gal) autoantibodies. In:Peter J.B., Shoenfeld Y., eds. Autoantibodies. Amsterdam: Elsevier, pp. 24-30.
18. Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109(2): 422-30.
19. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A., Khamashta M.A. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42(7): 1309-11.
20. George T.C., Bilsborough J., Viney J.L., Norment A.M. (2003) High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell mediated suppression in vitro. Eur J Immunol 33: 502-11.
21. Petrovsky N., Aguilar J.C. (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82(5): 488-96.
22. Morefield G.L., Sokolovska A., Jiang D., Hogen-Esch H., Robinson J.P., Hem S.L. (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13): 1588-95.
23. Brewer J.M. (2006) (How) do aluminum adjuvants work? Immunol Lett 102(1): 10-5.
24. Ghumman B., Bertram E.M.,Watts T.H. (1998) Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo. J Immunol 161(7): 3262-70.
25. Billiau A., Matthys P. (2001) Modes of action of Freud's adjuvants in experimental models of autoimmune diseases. J Leuk Biol 70(6): 849-60.
26. 2-glycoprotein I account for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109: 797-804.
27. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., Allegri F., Balestrieri G., Valesini G., Shoenfeld Y. (1994) Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naïve mice. J Autoimmunity 7: 441-5.
28. 2-glycoprotein I breaks tolerance to the murine molecule. Arthtitis Rheum 46(5): 1399-404.
29. 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. J Immunology 161: 5303-12.
30. Dimitrijevic Lj., Zivancevic-Simonovic S., Stojanovic M., Inic-Kanada A., Zivkovic I. (2004) The possible role of natural idiotopes in immune memory. Clin Dev Immunol 11(3/4): 281-85.
31. Dimitrijevic Lj., Radulovic M., Ciric B., Odrljin T., Jankov R.M., Marzari R. (1992) Immunochemical characterization of a murine monoclonal anti-idiotypic antibody. J Immunoassay 13(2): 181-96.
32. Pradeu T., Carosella E.D. (2006) On the definition of a criterion of immunogenicity. Proc Natl Acad Sci USA 103(47): 17858-61.
33. Kuroda E., Sugiura T., Zeki K., Yoshida Y., Yamashita U. (2000) Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: A possible mechanism to polarize Th2 type response in BALB/c mice. J Immunol 164: 2386-2395.
34. Constant S.L., Bottomly K. (1997) Induction of Th1 and Th2 CD4 T cell responses: the alternative approaches. Annu Rev Immunol 5: 297-322.
35. 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of cryptic epitope that activates pathogenic autoreactive T cells. Blood 105: 1552-7.
36. Meroni P.L., di Simone N., Testoni C., D'Asta M., Acaia B., Caruso A. (2004) Antiphospholipid antibodies as a cause of pregnancy loss. Lupus 13: 649-652.
37. Tran H.B., Macardle P.J., Hiscock J., Cavill D., Bradley J., Buyon J.P., Gordon T.P. (2002) Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arth Rheumatism 46(6): 1572-9.
38. Straszewski-Chavez S.L., Abrahams V.M., Mor G. (2005) The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocrine Rev 26: 877-97.
39. 2-glycoprotein I. Arthritis Rheum 43: 140-150.
40. Salamon J.E., Girardi G., Holers V.M. (2002) Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 61: 46-50.
41. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C.,Wetsel R.A., Lambris J.D., Holers V.M., Salmon J.E. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112: 1644-54.
42. 2-glycoprotein I only after conformational change. Blood 107: 1916-24.
43. Molina V., Shoenfeld Y. (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38(3): 235-45.
44. Radway-Bright E.L., InancM., Isenberg D.A. (1999) Animal models of the antiphospholipid syndrome. Rheumatology 38: 591-601.